NEW YORK (GenomeWeb News) – Roche today announced that the US Food and Drug Administration has given premarket approval for the firm's molecular test to assess a patient's viral load of cytomegalovirus.

The fully automated Cobas AmpliPrep/Cobas TaqMan CMV Test is the first FDA-approved laboratory test for quantifying CMV DNA in human plasma specimens, Roche said. The PCR-based test is designed to run on the Cobas AmpliPrep/Cobas TaqMan System and can be combined with the Cobas p 630 instrument, which provides an integrated pre-analytical primary tube handling solution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.